• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » CerviLenz plus progesterone could halve preterm birth risk

CerviLenz plus progesterone could halve preterm birth risk

June 1, 2010 By MedCity News

MedCity News logo

By Mary Vanac

CerviLenz is a simple, low-tech medical device that prompts a “why didn’t I think of that?” response from many obstetricians.

Yet the device that quickly, accurately and inexpensively measures a pregnant woman’s cervix could help answer the $26 billion-a-year problem of preterm birth in the United States.

And CerviLenz, the Chagrin Falls, Ohio, company commercializing the device, is aiming at a yet-to-emerge market that would use its product as a screening tool during all pregnancies to work with a progesterone drug to halve the risk of that problem.

While that market develops, CerviLenz is targeting the obstetricians, nurse-midwives, and labor and delivery nurses who need to know now whether a patient is in preterm labor.

The cost of preterm birth is staggering. In a 2006 report, the National Academies put the cost at $26 billion a year in the United States alone, which “constitutes a public health concern that costs society” in hardship and grief, not to mention dollars.

And the problem is getting worse. “The preterm birth problem has been growing over the last decade,” said Dr. Michael Ross, a maternal fetal medicine specialist in Torrance, Cal., and medical director for CerviLenz. “Prematurity accounts for 70 percent of prenatal morbidity. So it’s probably the most significant factor in obstetrics, in terms of numbers.”

That’s why the National Institutes of Health has been researching preterm birth for decades. In the 1980s, the institutes studied 3,000 pregnant women during its landmark Preterm Prediction Study. One of the conclusions of the study: a short cervical length is the best predictor of preterm birth.”That’s been replicated hundreds of times around the world,” said Dean Koch, president and chief executive of CerviLenz.

Dr. Rosalyn Baxter-Jones, an obstetrician and gynecologist in San Diego, Cal., knew the predictive value of cervical length, but she was aggravated by the inability to accurately measure a patient’s cervix. The only test available — vaginal ultrasound — was expensive and took a couple days to complete. Patients who were in premature labor couldn’t wait.

“This is ridiculous,” Baxter-Jones remembers saying to herself. So she sat down and sketched a device that could instantly measure the cervix. Within six months, Baxter-Jones was testing a prototype.

Ross, chairman of the obstetrics and gynecology department at Harbor/UCLA Medical Center where the device was being tested, thought it had “great potential as a screening tool.” Eventually, Ross bought the device assets, hired Koch, and helped start CerviLenz to commercialize it.

Koch’s experience made him an apt choice for CerviLenz. He had been leading sales and marketing at Adeza Biomedical Corp., a Sunnyvale, Cal., developer of women’s health products, including FullTerm, a fetal fibronectin test to assess the risk of preterm birth, and Gestiva, a progesterone drug that could be used to prevent preterm birth.

Cytyc Corp. in Marlborough, Mass., bought Adeza for $450 million in March 2007. By May of that year, Cytyc was merging with Hologic Inc. in Bedford, Mass., in a $6.2 billion stock deal.

“We sold that company for a lot of money right before I met Michael [Ross],” Koch said. “I was in the process of evaluating what I was going to do next. Michael asked me to start this company with him.”

Though Adeza had developed a test for the breakdown of fetal fibronectin — the protein that connects a developing baby to the uterus — as a predictor of preterm birth, the NIH says a short cervical length is still the best predictor. Developing the CerviLenz device became the next step in Koch’s preterm birth career.

Ross wanted Koch to move to Cal. to start their company. But Koch, who was born in Cleveland and lived near Columbus while working for Adeza, was impressed with how BioEnterprise, the bioscience company developer in northeast Ohio, helped first-time CEOs. So in March 2008, he chose Chagrin Falls for his business home.

In May of that year, CerviLenz landed its first investment — $350,000 from JumpStart Inc., the venture development organization in Cleveland. A few months later, the company raised an additional $315,000 from North Coast Angel Fund in Cleveland and some of its members.

Koch used the money to redesign his device, which already had Food & Drug Administration approval to be sold. “So we knew while the device was clever and useful, it also was not optimal,” he said. “It also had too many parts to be manufactured at a low cost.” He chose Interplex Medical LLC in Millford, Ohio, near Cincinnati to redesign and make the device.

A year later, CerviLenz raised $4 million from venture firms Arboretum Ventures in Ann Arbor, Mich. and Chrysalis Ventures in Louisville, Ky. to take its device through clinical testing and into the market. “We invested in CerviLenz in April of 2009,” said Koleman Karleski, Chrysalis Ventures’ managing partner. “It’s an exciting, young healthcare company.”

The company also used the investment to develop online materials to train professionals how to use its device and develop a “giving back” program through which it supports mother and child care worldwide.

In mid-May, CerviLenz did a staged launch of its device at the American Academy of Obstetricians and Gynecologists annual meeting in San Francisco. “It’s really at the stage of demonstrating commercial potential,” Koch said. “So, right now, we’re focusing on about 25 customers around the country who, over the next few weeks, are going to start their evaluations” of the disposable CerviLenz device to triage women in emergency rooms for premature labor.

Most of those women will be in false labor and will be sent home. But “if her cervix is very short and she’s premature, I would admit her and treat her with medications to stop the contractions,” Ross said.

In addition to demonstrating the clinical effectiveness of the device, Koch and his 11 employees want to show a limited number of hospital customers that they can sell, deliver and train people to use their $45 device before throwing wide the sales door.

“Although we are pricing our device modestly, we’ll be able to generate high margins,” he said. “We will likely need an additional round of capital about a year from now, probably in the $5 million range. That’ll be to accelerate our sales and marketing activities.”

In the meantime, the NIH will continue its studies of using progesterone as a prophylactic treatment to reduce the risk of preterm birth — not just as a way to stop premature labor. And the FDA could consider approving a drug for that use. Only then would doctors begin using CerviLenz as a routine screening tool during most pregnancies.

“We feel over the next year or two years as those studies are completed, the stance will change,” Koch said. “So we feel we’ll be demonstrating our usefulness in this preterm labor marketplace first. And as that market develops, we’ll be in a good position to play a role in helping to bring that drug to the right women at the right time.”

Filed Under: Business/Financial News, Gynecological, News Well, Women's Health Tagged With: CerviLenz

In case you missed it

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Acutus Medical ticks up on revenue beat, missed EPS in Q2 results
  • ResMed expects steady growth over the next year
  • Ambu is letting go of 200 employees
  • Medtronic has Class I recall for low-shock risk in ICDs
  • Titan Medical to start manufacturing Enos systems later this year
  • ZimVie sales down more than 11% in Q2 as it streamlines after spinoff
  • Cardinal Health’s CFO to move up to corner office
  • Levita Magnetics raises $26M for Magnetic-Assisted Robotic Surgery platform
  • Data supports use of Channel Medsystems Cerene cryotherapy
  • The 10 largest orthopedic device companies in the world
  • Nanopath raises $10M Series A for women’s health diagnostics
  • Avenda wins FDA IDE nod for AI-enabled prostate cancer therapy
  • NuVasive chief commercial officer Massimo Calafiore is stepping down
  • Preparing your medical device company for challenging market conditions
  • Dentsply Sirona replaces chief accounting officer amid internal investigation
  • Haemonetics stock rises on Street-beating Q1, raised guidance

RSS From Medical Design & Outsourcing

  • The 24 best medical device innovations of 2022
    The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products designed to improve the human condition.… […]
  • FDA issues new COVID-19 testing guidance to avoid false negatives
    COVID-19 testing should be repeated following a negative result on any antigen test, the FDA said in a move that could increase demand for diagnostics manufacturers. The latest guidance from the federal health agency is for negative COVID-19 antigen test results regardless of the presence or absence of symptoms. The federal agency said recent studies… […]
  • Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production
    Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility. The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing. “Confluent has experienced consistent and strong growth in… […]
  • FDA’s breakthrough medical device designations tally nears 700
    Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted almost 700 designations over the past seven years under a voluntary program for expedited regulatory review of medical devices and combination products that facilitate more effective treatment or diagnosis of serious diseases. According to recent metrics published by FDA, the agency has issued a total of… […]
  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]
  • GE Healthcare picks AI imaging startups for inaugural Edison Accelerator
    GE Healthcare and Nex Cubed have selected seven companies focused on artificial-intelligence-augmented medical imaging for the first cohort of the Edison Accelerator in Canada. The companies will be matched with mentors and test their technologies with GE’s new Edison Digital Health Platform over the next three months. The program will end with innovation showcase presentations… […]
  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy